Nicotinamide ( DrugBank: Nicotinamide )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
49	Systemic lupus erythematosus	1

6. Parkinson disease

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03568968 (ClinicalTrials.gov)	May 15, 2020	14/6/2018	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Drug: Placebo	Haukeland University Hospital	NULL	Recruiting	18 Years	N/A	All	400	N/A	Norway
2	NCT03816020 (ClinicalTrials.gov)	March 9, 2019	7/12/2018	NAD-supplementation in Drug naïve Parkinson's Disease	NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Completed	18 Years	N/A	All	30	N/A	Norway
3	EUCTR2004-005034-39-GB (EUCTR)	17/05/2005	20/04/2005	Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease	Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease	Idiopathic Parkinson's disease	Trade Name: Nicotinamide Product Name: NICOTINAMIDE INN or Proposed INN: Nicotinamide	Queen Elizabeth Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03260166 (ClinicalTrials.gov)	August 31, 2017	10/8/2017	Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus	An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus	Cutaneous Lupus Erythematosus;Systemic Lupus Erythematosus Rash	Drug: nicotinamide	Second Xiangya Hospital of Central South University	National Natural Science Foundation of China;Hunan Provincial Natural Science Foundation of China;National Key Clinical Specialty Construction Project of China	Active, not recruiting	18 Years	65 Years	All	40	Phase 2	China